As­traZeneca, Io­n­is boast full PhI­II win for AT­TR drug un­der re­view

With their rare dis­ease drug al­ready in the FDA’s doors, Io­n­is and As­traZeneca are get­ting an­oth­er boost from new da­ta that they say com­plete the pos­i­tive pic­ture.

The topline Phase III win un­der­scores how eplon­ter­sen, an an­ti­sense com­pound that As­traZeneca paid Io­n­is $200 mil­lion up­front to part­ner on, could help pa­tients with hered­i­tary transthyretin-me­di­at­ed amy­loid polyneu­ropa­thy (AT­TRv-PN) by low­er­ing the lev­els of a key bio­mark­er, re­lieve symp­toms and im­prove qual­i­ty of life.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER